Clinical Study
Evaluating the Efficacy of Treatment with a GnRH Analogue in Patients with Central Precocious Puberty
Table 3
Characteristics of patients without HPG axis suppression (mean ± SD) (range).
| | Treatment duration | Chronological age
(years) | BMI
SDS | Stage of puberty
(median) (range) | Basal LH (mIU/mL) | Peak LH (mIU/mL) | E2 (pg/mL) |
| | Pretreatment () | 8.6 ± 1.0
(7.0–10.1) | 0.9 ± 0.8
(0.7–2.2) | 3 (2–4) | 2.2 ± 3.3 (0.1–10.3) | 11.1 ± 10.6 (5.6–27.1) | 32.9 ± 24.0 (7.0–68.3) | | 3rd month () | 8.9 ± 1.0
(7.3–10.4) | 0.8 ± 0.7
(0.7–2.0) | 3 (1–4) | 0.1 ± 0.0 (0.1–0.2) | 4.7 ± 1.9 (3.0–8.4) | 13.7 ± 6.9 (7.0–22.6) | | 6th month () | 9.5 ± 1.2
(7.5–10.5) | 0.9 ± 0.6
(0.8–2.1) | 3 (2–4) | 0.4 ± 0.1 (0.2–0.6) | 4.8 ± 0.8 (3.8–6.0) | 14.1 ± 9.8 (7.0–30.8) | | 9th month () | 9.7 ± 1.6
(7.8–10.8) | 0.9 ± 1.0
(0.8–2.2) | 3 (2–4) | 0.4 ± 0.1 (0.4–0.6) | 3.8 ± 0.3 (3.6–4.2) | 18.6 ± 7.6 (11.8–26.8) |
|
|
BMI: body mass index; SDS: standard deviation score.
|
